[go: up one dir, main page]

DE69815310D1 - Zubereitungen zur tumorbehandlung enthaltend hai-knorpelextrakte und antineoplastische mittel - Google Patents

Zubereitungen zur tumorbehandlung enthaltend hai-knorpelextrakte und antineoplastische mittel

Info

Publication number
DE69815310D1
DE69815310D1 DE69815310T DE69815310T DE69815310D1 DE 69815310 D1 DE69815310 D1 DE 69815310D1 DE 69815310 T DE69815310 T DE 69815310T DE 69815310 T DE69815310 T DE 69815310T DE 69815310 D1 DE69815310 D1 DE 69815310D1
Authority
DE
Germany
Prior art keywords
preparations
antineoplastic agents
shark cartilage
tumor treatment
treatment containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69815310T
Other languages
English (en)
Other versions
DE69815310T2 (de
Inventor
Eric Dupont
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cosciens Biopharma Inc
Original Assignee
Les Laboratories Aeterna Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Les Laboratories Aeterna Inc filed Critical Les Laboratories Aeterna Inc
Publication of DE69815310D1 publication Critical patent/DE69815310D1/de
Application granted granted Critical
Publication of DE69815310T2 publication Critical patent/DE69815310T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/60—Fish, e.g. seahorses; Fish eggs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
DE1998615310 1997-03-11 1998-03-11 Zubereitungen zur tumorbehandlung enthaltend hai-knorpelextrakte und antineoplastische mittel Expired - Fee Related DE69815310T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CA2199694 1997-03-11
CA2199694 1997-03-11
PCT/CA1998/000202 WO1998040088A1 (en) 1997-03-11 1998-03-11 Compositions for treating tumors containing shark cartilage extracts and anti-neoplastic agents

Publications (2)

Publication Number Publication Date
DE69815310D1 true DE69815310D1 (de) 2003-07-10
DE69815310T2 DE69815310T2 (de) 2004-04-22

Family

ID=4160148

Family Applications (1)

Application Number Title Priority Date Filing Date
DE1998615310 Expired - Fee Related DE69815310T2 (de) 1997-03-11 1998-03-11 Zubereitungen zur tumorbehandlung enthaltend hai-knorpelextrakte und antineoplastische mittel

Country Status (18)

Country Link
US (2) US6383522B1 (de)
EP (1) EP0967987B1 (de)
JP (1) JP2001500899A (de)
KR (1) KR100417612B1 (de)
CN (2) CN1824317A (de)
AT (1) ATE241993T1 (de)
AU (1) AU745769B2 (de)
BR (1) BR9808858A (de)
CA (1) CA2281570C (de)
DE (1) DE69815310T2 (de)
DK (1) DK0967987T3 (de)
ES (1) ES2200316T3 (de)
IL (1) IL131701A (de)
NO (1) NO322847B1 (de)
NZ (1) NZ337376A (de)
PT (1) PT967987E (de)
RU (1) RU2195946C2 (de)
WO (1) WO1998040088A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
GB0121285D0 (en) 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
WO2003026574A2 (en) * 2001-09-24 2003-04-03 Au Jessie L-S Methods and compositions to determine the chemosensitizing dose of suramin used in combination therapy
PE20030701A1 (es) 2001-12-20 2003-08-21 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
US8309603B2 (en) 2004-06-07 2012-11-13 University Of Tennessee Research Foundation SARMs and method of use thereof
JPWO2004083257A1 (ja) * 2003-03-20 2006-06-22 ホソカワミクロン株式会社 軟骨魚類から単離されたプロテオグリカンおよびその製造方法
US7485707B2 (en) * 2003-07-02 2009-02-03 Solux Corporation Thermally stable crystalline epirubicin hydrochloride and method of making the same
US9889110B2 (en) 2004-06-07 2018-02-13 University Of Tennessee Research Foundation Selective androgen receptor modulator for treating hormone-related conditions
US9884038B2 (en) 2004-06-07 2018-02-06 University Of Tennessee Research Foundation Selective androgen receptor modulator and methods of use thereof
WO2006059236A2 (en) * 2004-11-16 2006-06-08 Aeterna Zentaris Inc. Method of using cartilage extract for increasing blood parameters
PL2298815T3 (pl) 2005-07-25 2015-08-31 Emergent Product Dev Seattle Zmniejszenie ilości komórek B przy użyciu cząsteczek wiążących specyficznych dla CD20 i CD37
EP1930017B1 (de) 2005-09-29 2012-05-23 Maruha Nichiro Seafoods, Inc. Zusammensetzung zur prävention und behandlung von krankheiten von erwachsenen
WO2007146968A2 (en) 2006-06-12 2007-12-21 Trubion Pharmaceuticals, Inc. Single-chain multivalent binding proteins with effector function
US9730908B2 (en) 2006-08-24 2017-08-15 University Of Tennessee Research Foundation SARMs and method of use thereof
US10010521B2 (en) 2006-08-24 2018-07-03 University Of Tennessee Research Foundation SARMs and method of use thereof
US9844528B2 (en) 2006-08-24 2017-12-19 University Of Tennessee Research Foundation SARMs and method of use thereof
CN101990439A (zh) * 2007-07-06 2011-03-23 特鲁比昂药品公司 具有置于c末端的特异性结合结构域的结合肽
US7968603B2 (en) 2007-09-11 2011-06-28 University Of Tennessee Research Foundation Solid forms of selective androgen receptor modulators
ATE513856T1 (de) * 2008-04-11 2011-07-15 Emergent Product Dev Seattle Cd37-immuntherapeutikum und kombination mit bifunktionellem chemotherapeutikum davon
US9622992B2 (en) 2012-07-13 2017-04-18 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US10258596B2 (en) 2012-07-13 2019-04-16 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US9744149B2 (en) 2012-07-13 2017-08-29 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
EP3352760A4 (de) 2015-09-21 2019-03-06 Aptevo Research and Development LLC Cd3-bindende polypeptide
WO2017201200A1 (en) * 2016-05-19 2017-11-23 Orphagen Pharmaceuticals, Inc. Therapeutic compositions containing rar-alpha antagonists

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE28093E (en) 1962-02-28 1974-07-30 Wound-healing cartilage powder
US3478146A (en) 1965-02-26 1969-11-11 Leslie L Balassa Wound-healing cartilage powder extracting process
US3966908A (en) 1973-11-29 1976-06-29 Lescarden Ltd. Method of treating degenerative joint afflictions
US4042457A (en) 1975-11-10 1977-08-16 Rush-Presbyterian-St. Luke's Medical Center Preparation of tissue invasion inhibitor and method of treatment utilizing the inhibitor
US4212857A (en) 1976-10-29 1980-07-15 Lescarden Ltd. Method for stimulating the production of immunoglobulin and total complement
US4822607A (en) * 1976-10-29 1989-04-18 Lescarden Ltd. Anti-tumor agent and method
US4243582A (en) 1979-04-26 1981-01-06 Monsanto Company Novel glycoproteins from bovine cartilage
US4350682A (en) * 1979-05-11 1982-09-21 Lescarden Ltd. Cartilage extraction processes and products
US4356261A (en) 1980-04-22 1982-10-26 Rush-Presbyterian-St. Luke's Medical Center Anti-invasion factor containing cultures
US4456589A (en) 1982-07-08 1984-06-26 Genetic Laboratories, Inc. Preparation of animal tissues for surgical implantation in human recipients
US4473551A (en) 1982-08-23 1984-09-25 Faxon Pharmaceuticals, Inc. Anti-inflammatory composition
JPS5939828A (ja) 1982-08-28 1984-03-05 Ajinomoto Co Inc 抗腫瘍活性物質の製造方法
US4444752A (en) 1982-09-13 1984-04-24 Lescarden Ltd. Method for treating progressive systemic sclerosis
US4469676A (en) 1983-06-21 1984-09-04 Michel Hecmati Method for eliminating wrinkles occurring in the human skin
JPS60178820A (ja) 1984-02-22 1985-09-12 Ajinomoto Co Inc 抗腫瘍活性物質の製造方法
US4656137A (en) 1985-09-12 1987-04-07 Lescarden Inc Method of processing animal cartilage
US4749522A (en) 1985-10-31 1988-06-07 Angio-Medical Corporation Supercritical fluid extraction of animal derived materials
US4746729A (en) 1986-07-30 1988-05-24 Kuettner Klaus E Cartilage-derived leukocyte elastase-inhibitor
US5135919A (en) 1988-01-19 1992-08-04 Children's Medical Center Corporation Method and a pharmaceutical composition for the inhibition of angiogenesis
US5096892A (en) 1988-05-27 1992-03-17 The Children's Medical Center Corporation Arylsulfatase inhibition and potentiation of angiostatic steroids and heparin
JPH06509791A (ja) * 1990-01-25 1994-11-02 チルドレンズ　ホスピタル 血管形成抑制のための方法と組成物
US5075112A (en) 1990-02-12 1991-12-24 Cartilage Technologies Inc. Method of and dosage unit for inhibiting angiogenesis or vascularization in an animal using shark cartilage
WO1993009766A1 (en) 1991-11-15 1993-05-27 Arthro Research And Development Corporation Method for treatment of acute and chronic painful arthropathic conditions in human and other mammals
WO1994012510A1 (en) 1992-11-30 1994-06-09 Lane I William Processing shark cartilage
KR100389223B1 (ko) 1993-07-19 2003-10-08 안지오제네시스 테크놀로지스, 인코포레이티드 생체내통로관강을개방유지하기위한스텐트및이의제조방법
US5618925A (en) * 1994-04-28 1997-04-08 Les Laboratories Aeterna Inc. Extracts of shark cartilage having an anti-angiogenic activity and an effect on tumor regression; process of making thereof
US6025334A (en) 1994-04-28 2000-02-15 Les Laboratoires Aeterna Inc. Extracts of shark cartilage having anti-collagenolytic, anti-inflammatory, anti-angiogenic and anti-tumoral activities; process of making, methods of using and compositions thereof
US6028118A (en) 1996-08-08 2000-02-22 Les Laboratoires Aeterna Inc. Methods of using extracts of shark cartilage
RU2066181C1 (ru) * 1994-06-02 1996-09-10 Онкологический научный центр им. Н.Н.Блохина Противоопухолевое средство
US5583153A (en) 1994-10-06 1996-12-10 Regents Of The University Of California Use of taxol in the treatment of rheumatoid arthritis
WO1996023512A1 (en) * 1995-02-03 1996-08-08 Les Laboratoires Aeterna Inc. Extracts of shark cartilage, process of production and uses thereof
US5843920A (en) 1996-09-16 1998-12-01 Biocell Technology, Llc Anionic saccharides for extraction of anti-angiogenic protein from cartilage
US6168807B1 (en) 1998-07-23 2001-01-02 Les Laboratoires Aeterna Inc. Low molecular weight components of shark cartilage, processes for their preparation and therapeutic uses thereof

Also Published As

Publication number Publication date
CA2281570C (en) 2003-09-23
AU745769B2 (en) 2002-03-28
EP0967987A1 (de) 2000-01-05
CN1245993C (zh) 2006-03-22
US6383522B1 (en) 2002-05-07
US6855338B2 (en) 2005-02-15
US20020146462A1 (en) 2002-10-10
CN1824317A (zh) 2006-08-30
ATE241993T1 (de) 2003-06-15
CA2281570A1 (en) 1998-09-17
RU2195946C2 (ru) 2003-01-10
IL131701A0 (en) 2001-03-19
EP0967987B1 (de) 2003-06-04
NZ337376A (en) 2002-02-01
HK1026364A1 (en) 2000-12-15
BR9808858A (pt) 2000-08-01
JP2001500899A (ja) 2001-01-23
KR20000075929A (ko) 2000-12-26
PT967987E (pt) 2003-10-31
NO994274L (no) 1999-11-09
AU6605598A (en) 1998-09-29
NO322847B1 (no) 2006-12-11
IL131701A (en) 2005-03-20
CN1250375A (zh) 2000-04-12
WO1998040088A1 (en) 1998-09-17
NO994274D0 (no) 1999-09-02
ES2200316T3 (es) 2004-03-01
DE69815310T2 (de) 2004-04-22
DK0967987T3 (da) 2003-09-22
KR100417612B1 (ko) 2004-02-05

Similar Documents

Publication Publication Date Title
ATE241993T1 (de) Zubereitungen zur tumorbehandlung enthaltend hai- knorpelextrakte und antineoplastische mittel
SG170612A1 (en) Antineoplastic combinations
SG157951A1 (en) Cripto blocking antibodies and uses thereof
IL144294A0 (en) P53 inhibitors and therapeutic use of the same
DE69739758D1 (de) Vakzine zur behandlung von lymphomen und leukämie
DE69905170D1 (en) Thiazolopyrimidinderivate
MY136095A (en) Use of human anti-ctla-4 antibodies for treatment of cancer
IL163573A0 (en) Conjugates of therapeutic or cytotoxic agents and biologically active peptides
NZ332720A (en) Therapeutic uses of bactericidal/permeability increasing (BPI) protein to treat human meningococcemia
MY138883A (en) Use of asiatic acid for treatment of cencer
TR200100054T2 (tr) Paroksetin metansülfonat
MXPA04003674A (es) Uso mejorado de compuesto antitumoral en terapia de cancer.
MY164077A (en) Compositions and uses of et743 for treating cancer
PT1109571E (pt) Metodos de tratamento da hipertensao e composicoes para utilizacao nesses metodos
IL150984A0 (en) Modified cytokines for use in cancer therapy
ATE344670T1 (de) Synergistische kombination zur behandlung von kolorektalkarzinom
BR9814419A (pt) "combinação de compostos de benzociclo-heptapiridina e drogas antineopláticas para tratamento de doenças proliferativas"
FR2765483B1 (fr) Medicament destine a traiter les dysfonctions erectiles
DK1133296T3 (da) Ny terapeutisk anvendelse af nicergolin
TR200002939T2 (tr) Paroksetin maleat
AU1128801A (en) Agents for treating human diseases, especially for treating tumors such as colonic cancers and melanomas or for regenerating tissue and promoting hair growth
MD980129A (en) Antiherpetic remedy
GB9723824D0 (en) Cytostatic agents
PL365075A1 (en) Combinations of dalfopristine/quinupristine with cefpirome
MXPA05002477A (es) Asialo-interferones y el tratamiento de cancer de higado.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: AETERNA ZENTARIS INC., QUEBEC, CA

8339 Ceased/non-payment of the annual fee